Previous close | 0.2900 |
Open | 0.2900 |
Bid | 0.0000 |
Ask | 1.4000 |
Strike | 23.00 |
Expiry date | 2024-06-21 |
Day's range | 0.2900 - 0.2900 |
Contract range | N/A |
Volume | |
Open interest | 321 |
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
Alkermes plc (Nasdaq: ALKS) today announced plans to present three posters related to ALKS 2680 at SLEEP 2024, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 1-5, 2024 in Houston. ALKS 2680 is the company's novel, investigational, oral orexin 2 receptor (OX2R) agonist in development as a once-daily treatment for narcolepsy.